SEATTLE--(BUSINESS WIRE)--Nativis, Inc., a clinical stage life science, bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced encouraging in vitro data supporting the use of ultra-low radiofrequency energy (ulRFETM) to disrupt signaling pathways in order to inhibit target mRNA and protein expression. Dr. Xavier Figueroa of Nativis will present the data at the 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, to be held November 17-20, 2016, at the Fairmont Princess Hotel in Scottsdale, Arizona.
Data from the in vitro studies evaluating Nativis’ proprietary ulRFE technology demonstrate the ability of ulRFE to replicate the mechanism of action of solvated molecules and impact biological signaling pathways. Blocking EGFR and PLK1 genes using a unique ulRFE resulted in a 30-70 percent reduction in mRNA expression and approximately 40 percent inhibition of protein expression. The study also validated the specificity of cellular EGFR knockdown and found that ulRFE-mediated knockdown of EGFR and PLK1 was associated with a decrease in U87 GBM cell proliferation.
“The initial data demonstrate that specific ulRFE can be used to knock down specific cellular genes, which can impact key pathways associated with cancer signaling,” stated Chris Rivera, Nativis’ Chief Executive Officer. “We believe our novel technology has the potential to transform the way we treat cancer. With these encouraging data in hand, we will continue to develop the Nativis Voyager® system for the treatment of Glioblastoma Multiforme with the aim to expand to additional indications in the future.”
About The Society for Neuro-Oncology
The Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education. The Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults. The SNO annual meeting includes presentations of the latest cutting edge data as well as offering educational sessions to attendees.
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. The company invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE™) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain. More information is available at www.nativis.com
